Crescent Biopharma, Inc. (NASDAQ:CBIO) — Market Cap & Net Worth
Market Cap & Net Worth: Crescent Biopharma, Inc. (CBIO)
Crescent Biopharma, Inc. (NASDAQ:CBIO) has a market capitalization of $638.13 Million ($638.13 Million) as of September 18, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #11053 globally and #2886 in its home market, demonstrating a -16.03% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Crescent Biopharma, Inc.'s stock price $17.18 by its total outstanding shares 37143940 (37.14 Million). Also see Crescent Biopharma, Inc. total assets for a full breakdown of the balance sheet.
Crescent Biopharma, Inc. Market Cap History: 2025 to 2026
Crescent Biopharma, Inc.'s market capitalization history from 2025 to 2026. Data shows growth from $440.53 Million to $638.13 Million (0.00% CAGR). Also see CBIO cash flow metrics for how efficiently the company converts equity into cash flow.
Crescent Biopharma, Inc. Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Crescent Biopharma, Inc.'s valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Crescent Biopharma, Inc. stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
40.62x
Crescent Biopharma, Inc.'s market cap is 40.62 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2025 | $440.53 Million | $10.84 Million | -$153.94 Million | 40.62x | N/A |
Competitor Companies of CBIO by Market Capitalization
Companies near Crescent Biopharma, Inc. in the global market cap rankings as of September 18, 2026. Review tangible equity quality of Crescent Biopharma, Inc. to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Crescent Biopharma, Inc. by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
Crescent Biopharma, Inc. Historical Marketcap From 2025 to 2026
Between 2025 and today, Crescent Biopharma, Inc.'s market cap moved from $440.53 Million to $ 638.13 Million, with a yearly change of 0.00%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $638.13 Million | +44.86% |
| 2025 | $440.53 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of Crescent Biopharma, Inc. was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $638.13 Million USD |
| MoneyControl | $638.13 Million USD |
| MarketWatch | $638.13 Million USD |
| marketcap.company | $638.13 Million USD |
| Reuters | $638.13 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Crescent Biopharma, Inc.
Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the develo… Read more